1. Different Potencies of Angiotensin Receptor Blockers at Suppressing Adrenal β-Arrestin1–Dependent Post-Myocardial Infarction Hyperaldosteronism
- Author
-
Anastasios Lymperopoulos, Emmanuel Sturchler, Samalia Dabul, Karlee Walklett, Patricia McDonald, Walter J. Koch, Dilayda Garcia, Giuseppe Rengo, Ashley Bathgate-Siryk, Lymperopoulos, Anastasio, Sturchler, Emmanuel, Bathgate-Siryk, Ashley, Dabul, Samalia, Garcia, Dilayda, Walklett, Karlee, Rengo, Giuseppe, Mcdonald, Patricia, and Koch, Walter J.
- Subjects
medicine.medical_specialty ,Myocardial Infarction ,Tetrazoles ,Infarction ,Benzimidazole ,Post myocardial infarction ,chemistry.chemical_compound ,Angiotensin II Type 1 Receptor Blocker ,Internal medicine ,Hyperaldosteronism ,medicine ,Animals ,Aldosterone ,Tetrazole ,Angiotensin II receptor type 1 ,Animal ,business.industry ,Biphenyl Compounds ,Valine ,medicine.disease ,Angiotensin II ,Rats ,Endocrinology ,chemistry ,Heart failure ,Rat ,Valsartan ,Benzimidazoles ,business ,Cardiology and Cardiovascular Medicine ,Angiotensin II Type 1 Receptor Blockers ,Hormone - Abstract
Aldosterone is 1 of the various hormones with detrimental functions for the failing heart, whose circulating levels are elevated post-myocardial infarction (MI) and in patients with chronic heart failure (HF) [(1)][1]. We have recently discovered that angiotensin II, acting through its type 1
- Full Text
- View/download PDF